1. Home
  2. KNRX vs BIAF Comparison

KNRX vs BIAF Comparison

Compare KNRX & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KNOREX LTD. Class A Ordinary Shares

KNRX

KNOREX LTD. Class A Ordinary Shares

N/A

Current Price

$1.17

Market Cap

10.9M

Sector

Technology

ML Signal

N/A

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

N/A

Current Price

$7.41

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KNRX
BIAF
Founded
2009
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
9.2M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
KNRX
BIAF
Price
$1.17
$7.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
26.4K
★ 7.4M
Earning Date
06-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 14.49
52 Week Low
$0.28
$0.33
52 Week High
$3.45
$20.35

Technical Indicators

Market Signals
Indicator
KNRX
BIAF
Relative Strength Index (RSI) 89.37 53.72
Support Level $0.35 $1.07
Resistance Level $1.46 $12.48
Average True Range (ATR) 0.11 1.44
MACD 0.06 -0.36
Stochastic Oscillator 75.71 29.69

Price Performance

Historical Comparison
KNRX
BIAF

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: